Undisclosed Clinical Candidate(s)

About LimmaTech Biologics

LimmaTech Biologics is a clinical-stage biotech focused on addressing the global antimicrobial resistance (AMR) crisis through novel vaccine development. The company utilizes a proprietary, self-adjuvanting, multivalent vaccine platform based on engineered E. coli to efficiently produce complex carbohydrate and protein vaccine candidates. Backed by leading investment funds and a team with decades of vaccine development experience, LimmaTech is rapidly expanding its pipeline to prevent infections caused by drug-resistant pathogens. Its mission is to deliver affordable, effective vaccines as a critical strategy to avert disease and reduce the threat of AMR.

Therapeutic Areas